蛋白质生物标志物用于卵巢肿瘤良恶性术前鉴别诊断的评估
这项探索性诊断研究连续纳入254例拟手术的附件肿块患者,术前用Luminex和ECLIA定量33种血清蛋白,计算单变量AUC并用多变量岭回归区分良恶性。CA125区分良恶性的单变量AUC最高(0.85,95%CI 0.79-0.89),联合CA72.4和HE4后AUC升至0.87;CA125、HE4、CA72.4、CA15.3和LAP在区分I期与II-IV期恶性时AUC≥0.80。
要点
- CA125区分良恶性附件肿块的AUC为0.85,联合CA72.4和HE4后升至0.87。
- CA125区分良性 vs 交界性肿瘤的单变量AUC最高(0.74)。
- CA125、HE4、CA72.4、CA15.3和LAP区分I期 vs II-IV期恶性时AUC≥0.80。
核心结论
- 结果证实CA125在识别恶性肿瘤中的主导作用。
- 其他标志物(HE4、CA72.4、CA15.3和LAP)可能有助于区分I期与II-IV期恶性肿瘤。
- 尚需进一步研究,并需探讨这些标志物在临床和超声恶性预测因素之上的附加价值。
研究设计与样本
- 探索性诊断研究,在鲁汶大学医院连续纳入254例拟手术的附件肿块患者。
- 肿瘤构成:良性128例、交界性42例、I期22例、II-IV期55例、继发性转移7例。
- 术前用多重高通量免疫分析(Luminex)和电化学发光免疫分析(ECLIA)定量33种血清蛋白。
- 计算单变量ROC曲线下面积(AUC),并用多变量岭逻辑回归结合后向消除区分良恶性,用自举法验证AUC。
主要发现
- CA125区分良恶性的单变量AUC最高,为0.85(95%CI 0.79-0.89)。
- CA125联合CA72.4和HE4后AUC升至0.87。
- 良性 vs 交界性肿瘤中,CA125单变量AUC最高(0.74)。
- 交界性 vs I期恶性之间,没有 promising 的蛋白。
- I期 vs II-IV期恶性中,CA125、HE4、CA72.4、CA15.3和LAP的单变量AUC≥0.80。
关键数值与推荐
- CA125区分良恶性的单变量AUC为0.85(95%CI 0.79-0.89)。
- CA125联合CA72.4和HE4区分良恶性的AUC为0.87。
- CA125区分良性 vs 交界性肿瘤的单变量AUC为0.74。
- CA125、HE4、CA72.4、CA15.3和LAP区分I期 vs II-IV期恶性的单变量AUC≥0.80。
临床怎么用
- 术前可用CA125作为识别附件肿块恶性的主要血清标志物。
- 联合CA72.4和HE4可小幅提高良恶性鉴别的AUC。
- HE4、CA72.4、CA15.3和LAP可能辅助区分I期与II-IV期恶性,但尚需进一步研究。
局限性
- 为探索性诊断研究,样本来自单一中心。
- 交界性 vs I期恶性之间未发现 promising 的蛋白标志物。
- 尚需进一步研究标志物相对于临床和超声恶性预测因素的附加价值。
- 需进一步研究聚焦于恶性肿瘤亚型之间的区分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the diagnostic value of tumor and immune related proteins in the discrimination between benign and malignant adnexal masses, and between different subgroups of tumors. METHODS: In this exploratory diagnostic study, 254 patients with an adnexal mass scheduled for surgery were consecutively enrolled at the University Hospitals Leuven (128 benign, 42 borderline, 22 stage I, 55 stage II-IV, and 7 secondary metastatic tumors). The quantification of 33 serum proteins was done preoperatively, using multiplex high throughput immunoassays (Luminex) and electrochemiluminescence immuno-assay (ECLIA). We calculated univariable areas under the Receiver Operating Characteristic Curves (AUCs). To discriminate malignant from benign tumors, multivariable ridge logistic regression with backward elimination was performed, using bootstrapping to validate the resulting AUCs. RESULTS: CA125 had the highest univariable AUC to discriminate malignant from benign tumors (0.85, 95% confidence interval 0.79-0.89). Combining CA125 with CA72.4 and HE4 increased the AUC to 0.87. For benign vs borderline tumors, CA125 had the highest univariable AUC (0.74). For borderline vs stage I malignancy, no proteins were promising. For stage I vs II-IV malignancy, CA125, HE4, CA72.4, CA15.3 and LAP had univariable AUCs ≥0.80. CONCLUSIONS: The results confirm the dominant role of CA125 for identifying malignancy, and suggest that other markers (HE4, CA72.4, CA15.3 and LAP) may help to distinguish between stage I and stage II-IV malignancies. However, further research is needed, also to investigate the added value over clinical and ultrasound predictors of malignancy, focusing on the differentiation between subtypes of malignancy.
引用
- Landolfo C, Achten ETL, Ceusters J, et al. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Gynecol Oncol. 2020. PMID: 32994054. doi:10.1016/j.ygyno.2020.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。